Hyphens Pharma bets big on Asean’s medical aesthetics boom

[SINGAPORE] Catalist-listed Hyphens Pharma wants to ride on the growing medical aesthetics market across South-east Asia, with the aim of becoming the region’s leading consumer healthcare group.

The pharmaceutical company is seeing a growing interest in this segment, as regional economic growth drives evolving consumer behaviours. A rising middle class has emerged – demonstrating greater willingness to invest in premium aesthetic procedures and dermatological products.

“Dermatology may be an underdeveloped category,” chief executive officer Lim See Wah told The Business Times in an interview. “Historically, it is always the acute diseases, the life-threatening diseases that took precedence. But with economic growth, ‘looking good, feeling good’ has become important.”